The efficacy and tolerability of omalizumab in patients with moderate to severe persistent allergic asthma in Malta : A real life experience

Trial Profile

The efficacy and tolerability of omalizumab in patients with moderate to severe persistent allergic asthma in Malta : A real life experience

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Mar 2017 Results (n=34) assessing sex differences in the efficacy, safety, and tolerability of omalizumab published in the Annals of Allergy, Asthma and Immunology.
    • 22 Nov 2013 New trial record
    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top